HPVScreen

The HPVSCREEN study is a pilot study implemented in order to verify the level of infection in the female population by HPV viruses with the focus on early and effective diagnosis of cervical cancer and the diseases preceding it. In the study, our scientists evaluated the prevalence of HPV infection of the cervix in a randomly selected group of women representing the female population in two age cohorts (women aged under 30 and women aged over 30) in various geographical areas of Slovakia.

About the project

The HPVSCREEN study is a pilot study implemented in order to verify the level of infection in the female population by HPV viruses with the focus on early and effective diagnosis of cervical cancer and the diseases preceding it. In the study, our scientists evaluated the prevalence of HPV infection of the cervix in a randomly selected group of women representing the female population in two age cohorts (women aged under 30 and women aged over 30) in various geographical areas of Slovakia.

 

The submitted study is a part of the project aimed at optimisation of the strategy for screening for cervical cancer in the Slovak population. The project should generate basic information about the prevalence of high-risk HPV subtypes in the general Slovak female population. After obtaining the data, an optimised screening algorithm will be designed taking into account the most recent scientific findings and implementation of new screening schemes in advanced countries (Germany, UK, and Austrlia) thus enabling early and effective diagnosis of cervical cancer – one of the most frequent types of cancer in women. The research project is also motivated by another fact: Not only in Slovakia, cervical carcinoma is a type of cancer that belongs to the top 5 cancers with the highest incidence and mortality in women with severe social impact even though there are available methods enabling screening, early diagnosis and treatment of precancerous stages. Therefore, the findings of the study may contribute with basic data that could be applicable not only locally but also globally.

 

The partners in the study:

  • MEDIREX GROUP ACADEMY, n.o. as the “project promoter”,
  • Approximately 30 centres, providers of healthcare in gynecology and obstetrics in Slovakia as project investigators,
  • 1000 patients from the Slovak Republic who met the inclusion and exclusion criteria of the study.

 

The patients included in the study will undergo a cervical smear, the specimen will be transferred into the liquid in the collection vial of the Liquid Based Cytology ThinPrep® pap test. Then the sample will undergo genetic test to detect presence of HPV viruses.

After completing the process of laboratory diagnosis, the detected finding will be entered into the e-CRF online system. Data collection in the patient pool was completed on 31 December 2017.

 

No specific therapy is validated by the study. This study serves solely for observation purposes and the schedule of visits in the medical office and all therapeutical regimes are indicated by the treating physician in line with conventional clinical practice.

Project activities

Patiet recruitment took place between 1 February 2017 and 31 December 2017. In this period, every patient who met the inclusion criteria was included in the study (until the number of patients reached 1000).

Data collection related to the patient pool was completed on 31 December 2017.

Statistical processing and evaluation of the collected data took place between 1 June 2017 and 1 June 2018.  

Professional supervision

MUDr. Pavol Janega, PhD.

Director, MEDIREX GROUP ACADEMY n.o.

pavol.janega@medirexgroupacademy.sk

+421 2 2082 9111